Reumatologia Clinica最新文献

{"title":"La actividad de la artritis psoriásica con afectación axial se correlaciona con el PsAID12","authors":"Jose Antonio Pinto Tasende ,&nbsp;Carlota Laura Iñiguez Ubiaga ,&nbsp;Victor Eliseo Quevedo Vila ,&nbsp;Luis Fernández Dominguez ,&nbsp;Francisco Jose Maceiras Pan ,&nbsp;Carlos García Porrúa","doi":"10.1016/j.reuma.2023.08.005","DOIUrl":"10.1016/j.reuma.2023.08.005","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the impact of the disease in patients with PsA in daily clinical practice and to evaluate its relationship with its axial activity.</p></div><div><h3>Methods</h3><p>A cross-sectional study was conducted in consecutive patients attended from January 2021 to December 2021 who met the CASPAR criteria, with clinical of inflammatory back pain and positive axial imaging, with or without peripheral involvement. Demographic, clinical, analytical data, HAQ index, PsAID12 and activity index (BASDAI and ASDAS-PCR) were also collected. Patients were divided into two groups, those with high impact and those with low impact according to PsAID results. Continuous variables are shown as median (Q1-Q3) and categorical variables as percentages and frequencies.</p></div><div><h3>Results</h3><p>Of the 269 patients evaluated with PsA, 72 patients with axial involvement were included, 40 men (55.6%), with a median age of 54.1 years and disease duration of 7 years. 28.3% of the patients were obese and serum CRP level was 0.45<!--> <!-->mg/dl (0.08-1.10). BASDAI was 4.2 (2.0-6.2) and ASDAS-PCR was 2.4 (1.5-3.2), which translates into 39.6% of patients in low activity or remission. The median PsAID total score was 3.9 (1.6–5.4), evaluated in 61 patients. The patients who achieved a PsAID12<!--> <!-->≤<!--> <!-->4 were 63%, mostly men and with lower CRP levels than PsAID<!--> <!-->≥<!--> <!-->4 patients. In addition, low impact measured by the PsAID12 was associated with low results in BASDAI and ASDAS-PCR.</p></div><div><h3>Conclusions</h3><p>Axial involvement reflected lower impact of the disease measured by PsAID12 and it is correlated with low activity measured by BASDAI and ASDAS-PCR.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135389955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CXCL10 as a biomarker of interstitial lung disease in patients with rheumatoid arthritis","authors":"Yasmine S. Makarem ,&nbsp;Elzahraa A. Ahmed ,&nbsp;Marwa Makboul ,&nbsp;Shimaa Farghaly ,&nbsp;Naima Mostafa ,&nbsp;Randa A. El Zohne ,&nbsp;Samar H. Goma","doi":"10.1016/j.reuma.2023.05.001","DOIUrl":"10.1016/j.reuma.2023.05.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Pulmonary involvement is a frequent and serious rheumatoid arthritis (RA) manifestation that affects 60%–80% of patients. CXCL10 is an inflammatory chemokine that regulates different biological responses, such as chemotaxis, angiogenesis, and inflammation.</p></div><div><h3>Aim</h3><p>This study aimed to identify the role of CXCL10 as a peripheral blood marker of RA-ILD and its correlation with disease activity.</p></div><div><h3>Patients and methods</h3><p><span>This cross-sectional study included 73 patients with RA (33 with </span>ILD and 40 without ILD). Pulmonary function tests and high-resolution computed tomography were performed. Blood samples were taken for complete blood count and blood chemistry analysis, and human interferon-inducible protein 10 (IP-10/CXCL10) level. Statistical Package for the Social Sciences (version 22) was used for all statistical calculations.</p></div><div><h3>Results</h3><p>The serum CXCL10 level and patient age (<em>r</em> <!-->=<!--> <!-->.393, <em>p</em> <!-->=<!--> <!-->.024), disease duration (<em>r</em> <!-->=<!--> <!-->.756, <em>p</em> <!-->&lt;<!--> <!-->0.001), erythrocyte sedimentation rate (<em>r</em> <!-->=<!--> <!-->.516, <em>p</em> <!-->=<!--> <!-->.002), C-reactive protein (<em>r</em> <!-->=<!--> <!-->.539, <em>p</em> <!-->=<!--> <!-->.001), and rheumatoid factor (<em>r</em> <!-->=<!--> <!-->.663, <em>p</em> <!-->&lt;<!--> <!-->.001) revealed a significant positive correlation. Furthermore, the Modified Health Assessment Questionnaire (<em>r</em> <!-->=<!--> <!-->−.418, <em>p</em> <!-->=<!--> <!-->.015) revealed a significant negative correlation. Patients with RA-ILD show significantly higher CXCL10 than those without ILD (<em>p</em> <!-->&lt;<!--> <!-->.001).</p></div><div><h3>Conclusion</h3><p>CXCL10 is a useful RA disease activity biomarker and is an RA-ILD-sensitive biomarker, also CXCL10 is a significant predictor for development of RA-ILD.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135387594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recomendaciones SER sobre el tratamiento de la uveítis","authors":"Emma Beltrán Catalán ,&nbsp;Noé Brito García ,&nbsp;Esperanza Pato Cour ,&nbsp;Santiago Muñoz Fernández ,&nbsp;Alejandro Gómez Gómez ,&nbsp;David Díaz Valle ,&nbsp;Marisa Hernández Garfella ,&nbsp;Félix Manuel Francisco Hernández ,&nbsp;M. del Mar Trujillo Martín ,&nbsp;Lucía Silva Fernández ,&nbsp;Gemma Villanueva ,&nbsp;Julio Suárez Cuba ,&nbsp;Ricardo Blanco","doi":"10.1016/j.reuma.2023.07.002","DOIUrl":"https://doi.org/10.1016/j.reuma.2023.07.002","url":null,"abstract":"<div><h3>Objective</h3><p>To develop evidence-based expert-consensus recommendations for the management of non-infectious, non-neoplastic, non-demyelinating disease associated uveitis.</p></div><div><h3>Methods</h3><p>Clinical research questions relevant to the objective of the document were identified, and reformulated into PICO format (patient, intervention, comparison, outcome) by a panel of experts selected based on their experience in the field. A systematic review of the available evidence was conducted, and evidence was graded according to GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria. Subsequently, recommendations were developed.</p></div><div><h3>Results</h3><p>Three PICO questions were constructed referring to uveitis anterior, non-anterior and complicated with macular edema. A total of 19 recommendations were formulated, based on the evidence found and/or expert consensus.</p></div><div><h3>Conclusions</h3><p>Here we present the first official recommendations of the Spanish Society of Rheumatology for the treatment of non-infectious and non-demyelinating disease associated uveitis. They can be directly applied to the Spanish healthcare system as a tool for assistance and therapeutic homogenisation.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49864402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-surgical treatment of aseptic olecranon bursitis: A systematic review","authors":"Ikwinder Preet Kaur ,&nbsp;Mohsin Sheraz Mughal ,&nbsp;Fawad Aslam ,&nbsp;Jennifer Schram ,&nbsp;Pankaj Bansal","doi":"10.1016/j.reuma.2023.02.006","DOIUrl":"https://doi.org/10.1016/j.reuma.2023.02.006","url":null,"abstract":"<div><h3>Objective</h3><p>Olecranon bursitis (OB), characterized by inflammation and fluid collection in the olecranon bursa is a commonly encountered out-patient condition. The data is heterogeneous regarding a stepwise and standardized approach to aseptic OB treatment and the efficacy of intra-bursal corticosteroid injections (CSI). The objective of this review is to systematically evaluate the non-surgical treatment options for aseptic OB.</p></div><div><h3>Methods</h3><p>This systematic review was conducted in accordance with PRISMA recommendations. The English and non-English literature search was performed in 5 medical databases to identify studies evaluating the treatment of OB. All included studies were evaluated for risk of bias (RoB) using the revised Cochrane RoB tool for randomized control trials (RCTs) and the Newcastle-Ottawa Scale (NOS) for case–control and cohort studies.</p></div><div><h3>Results</h3><p>For the final analyses, 2 RCTs and 2 observational studies were included. The RoB for the RCTs was high and both failed to demonstrate a significant difference in terms of the resolution of OB and bursal tenderness among various invasive and non-invasive treatment options. Corticosteroid injection (CSI) was associated with a significant decline in the duration of symptoms. However, it was associated with a higher number of complications including bursal infection and skin atrophy.</p></div><div><h3>Conclusion</h3><p>Based on the available data, it appears that the clinical resolution of aseptic OB can occur with conservative methods if implemented earlier in the disease course. Although CSI is more effective than other treatments, it should be reserved for refractory cases because of a higher complication rate.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49864441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice","authors":"Jordi Gratacós-Masmitja ,&nbsp;Emma Beltrán Catalán ,&nbsp;José Luis Álvarez Vega ,&nbsp;Ana Urruticoechea-Arana ,&nbsp;Concepción Fito ,&nbsp;Francisco Maceiras ,&nbsp;Joaquín María Belzunegui Otano ,&nbsp;Julia Fernández Melón ,&nbsp;Eugenio Chamizo Carmona ,&nbsp;Miguel Ángel Abad Hernández ,&nbsp;Inmaculada Ros Vilamajó ,&nbsp;Sonia Castro Oreiro ,&nbsp;Eva Pascual Alfonso ,&nbsp;Juan Carlos Torre Alonso ,&nbsp;on behalf of the PREVAIL team","doi":"10.1016/j.reuma.2023.06.007","DOIUrl":"10.1016/j.reuma.2023.06.007","url":null,"abstract":"<div><h3>Introduction</h3><p>Apremilast is approved for treatment of psoriasis and psoriatic arthritis (PsA). Real-world evidence on apremilast effectiveness in clinical practice is limited.</p></div><div><h3>Methods</h3><p>Observational study enrolling adult patients, across 21 Spanish centres, who had initiated apremilast in the prior 6 (±1) months and were biologic naive. Data were collected at routine follow-up visits 6 and 12 months after apremilast initiation. Primary outcome was 6 and 12-month persistence to apremilast. Secondary outcomes included Disease Activity for PsA (DAPSA), joint erosions, enthesitis, dactylitis, and patient-reported quality of life (QoL, measured using the PsA impact of disease [PsAID] questionnaire).</p></div><div><h3>Results</h3><p>We included 59 patients. Most had oligoarticular PsA, moderate disease activity, and high comorbidity burden. Three-quarters were continuing apremilast at 6 months and two-thirds at 12 months; mean (SD) apremilast treatment duration was 9.43 (1.75) months. DAPSA scores showed improved disease activity: one-third of patients in remission or low activity at apremilast initiation versus 62% and 78% at 6 and 12 months, respectively. Eleven of 46 patients with radiographic assessments had joint erosions at apremilast initiation and none at month 12. Median (<em>Q</em>1, <em>Q</em>3) number of swollen joints was 4.0 (2.0, 6.0) at apremilast initiation versus 0.0 (0.0, 2.0) at 12 months. Incidence of dactylitis and enthesitis decreased between apremilast initiation (35.6% and 28.8%, respectively) and month 12 (11.6% and 2.4%, respectively). Over two-thirds of patients had a PSAID-9 score &lt;4 (cut-off for patient-acceptable symptom state) at month 12.</p></div><div><h3>Conclusions</h3><p>In Spanish clinical practice, two-thirds of PsA patients continued apremilast at 12 months, with clinical benefits at the joint level, no radiographic progression of erosions, and a positive impact on patient-reported QoL.</p><p>Trial registration number Clinicaltrials.gov: <span>NCT03828045</span><svg><path></path></svg>.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1699258X23001456/pdfft?md5=2b5793cb7ef3c0ece1f920fa0423c83f&pid=1-s2.0-S1699258X23001456-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44663229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¿Se comporta la enfermedad pulmonar difusa igual en todas las enfermedades reumáticas? Revisión de la literatura","authors":"Diego Durán Barata,&nbsp;Andrea Pérez Figuera,&nbsp;Winnifer Briceño Franquiz,&nbsp;Beatriz Pintado Cort","doi":"10.1016/j.reuma.2022.10.005","DOIUrl":"10.1016/j.reuma.2022.10.005","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44540067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High frequency of gastrointestinal complaints, but insignificant prevalence of gluten-sensitive enteropathies in Brazilian fibromyalgia patients","authors":"Caio Bosquiero Zanetti ,&nbsp;Marco Antônio Gonçalves Pontes ,&nbsp;Eduardo Guimarães Hourneaux de Moura ,&nbsp;Diogo Souza Domiciano","doi":"10.1016/j.reuma.2022.12.004","DOIUrl":"https://doi.org/10.1016/j.reuma.2022.12.004","url":null,"abstract":"<div><h3>Introduction/Objectives</h3><p>Coeliac disease (CD) and non-coeliac gluten sensitivity (NCGS) cause symptoms like those seen in patients with fibromyalgia (FM) and functional gastrointestinal disorders. There is no consistent data on frequency of these symptoms and no study performed duodenal biopsies to investigate CD/NCGS in Brazilian FM patients. Therefore, we sought to verify the prevalence of CD/NCGS in FM patients and the association between gastrointestinal manifestations and FM symptoms.</p></div><div><h3>Material and methods</h3><p>Sixty-two individuals with FM (ACR2010) were recruited from FM outpatient clinics of a tertiary hospital. Clinical evaluation included the Widespread Pain Index (WPI), Severity Symptom Scale (SS), Polysymptomatic Distress Scale (PDS), and Fibromyalgia Impact Questionnaire (FIQ). Subjects were screened for the presence of coeliac antibodies and upper gastrointestinal endoscopy (duodenal biopsies) was performed for diagnosis of CD/NCGS.</p></div><div><h3>Results</h3><p><span>46 (74.2%) women reported at least one digestive symptom: constipation, abdominal distension, loss of weight/inappetence, and nausea/vomiting. Fourteen (31.8%) presented macroscopic duodenitis and 2(4.5%) had duodenal lymphocytic infiltrates, but none met CD criteria. In 1(1.6%) patient NCGS was confirmed. There was association between presence of any digestive symptom and WPI and SS (fatigue, waking up tired, cognition), but no difference on </span>FIQ between patients with and without gastrointestinal symptoms.</p></div><div><h3>Conclusion</h3><p>Gastrointestinal complaints were frequent and associated with increased degree of polysymptomatic distress in FM patients, but presence of these symptoms was not related to overall impact of FM over different dimensions of the patient's life. Moreover, the prevalence of CD/NCGS was very low. This suggests that screening for CD in Brazilian FM patients might not be cost-effective, since the frequency of CD/NCGS was very low.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49897128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between epicardial adipose tissue, systemic inflammatory diseases, and subclinical atheromatosis: A systematic review","authors":"Walter Masson ,&nbsp;Augusto Lavalle-Cobo ,&nbsp;Leandro Barbagelata ,&nbsp;Martin Lobo ,&nbsp;Juan Patricio Nogueira","doi":"10.1016/j.reuma.2022.10.001","DOIUrl":"https://doi.org/10.1016/j.reuma.2022.10.001","url":null,"abstract":"<div><h3>Background and aims</h3><p>Systemic inflammatory diseases could act as an unfavorable condition in which epicardial adipose tissue (EAT) becomes harmful to cardiovascular health. The objectives were: (a) to quantitatively compare the presence of EAT between patients with systemic inflammatory diseases and controls; (b) to analyze the association between EAT and subclinical atheromatosis in individuals with systemic inflammatory diseases.</p></div><div><h3>Methods</h3><p>Studies that have quantified EAT in a population with systemic inflammatory diseases compared to a control group, or that describe the association between EAT and the presence of subclinical atheromatosis in patients with systemic inflammatory diseases were included. A quantitative analysis was performed for the first objective. This systematic review was performed according to PRISMA guidelines.</p></div><div><h3>Results</h3><p>Twenty-one studies including 1448 patients with systemic inflammatory diseases, were considered eligible for this study. Patients with systemic inflammatory disease have a higher volume (MD: 10.4<!--> <!-->cm³ [1.8–19.1]; <em>p</em> <!-->&lt;<!--> <!-->0.01), higher thickness (MD: 1.0<!--> <!-->mm [0.8–1.2]; <em>p</em> <!-->&lt;<!--> <!-->0.01), and a statistically non-significant higher area (MD: 3.1<!--> <!-->cm² [1.0–5.2]; <em>p</em> <!-->=<!--> <!-->0.46) of EAT compared to the control group. Most studies reported a significant association between EAT and subclinical atheromatosis in patients with different systemic inflammatory diseases.</p></div><div><h3>Conclusion</h3><p>This study demonstrated that EAT is increased in patients with systemic inflammatory diseases compared with healthy controls, and that EAT measurement is closely correlated with subclinical atherosclerosis in these patients. The causality of this association should be tested in prospective studies.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49886031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic lupus erythematosus mimicking leprosy: A challenge to early diagnosis","authors":"Patrick Nunes Brito ,&nbsp;Danielle Pereira Barros ,&nbsp;Brenda Nunes Brito ,&nbsp;Rayza Brito Silva ,&nbsp;Marcus Emilio Costa Maciel ,&nbsp;Monica Camilo Nunes de Sousa","doi":"10.1016/j.reuma.2023.03.002","DOIUrl":"https://doi.org/10.1016/j.reuma.2023.03.002","url":null,"abstract":"<div><p>We describe a case of a male patient with systemic lupus erythematosus (SLE) and lupus nephritis. A patient who was initially diagnosed with multibacillary leprosy, an infectious disease, with clinical symptoms for two years. However, after hospitalization and investigation, his diagnosis was revoked and replaced with SLE. The aim of this study is to emphasize the importance of knowing the most important and significant clinical changes in SLE and thus allowing an accurate diagnosis, preventing disease progression with target organ involvement, and allowing better clinical management.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49897129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sesgos de género en la reumatología española: Percepciones y realidad","authors":"Concepción Delgado Beltrán ,&nbsp;Isabel Castrejón ,&nbsp;Blanca Hernández-Cruz ,&nbsp;María Luz García Vivar ,&nbsp;Rosario García de Vicuña ,&nbsp;Montserrat Romera Baures ,&nbsp;Patricia Carreira ,&nbsp;Esperanza Naredo ,&nbsp;Delia Reina ,&nbsp;María Galindo ,&nbsp;Cilia Peralta ,&nbsp;Blanca Varas de Dios ,&nbsp;Loreto Carmona","doi":"10.1016/j.reuma.2023.02.004","DOIUrl":"10.1016/j.reuma.2023.02.004","url":null,"abstract":"<div><h3>Objective</h3><p>To identify perceptions of gender bias in Spanish rheumatology and to quantify the involvement of both sexes in all areas of the specialty.</p></div><div><h3>Methods</h3><p>A survey was sent to all members of the SER on participation and perception of biases and of their own competencies, and actual data on participation in governing bodies, congresses, committees, and Spanish rheumatology departments in the last 5 years were reviewed.</p></div><div><h3>Results</h3><p>The survey was answered by 95 rheumatologist, 4.8% of SER members (14 men and 81 women), both groups being similar in terms of age, academic level, and position and work centre. No differences were detected in the distribution of work and non-work tasks between sexes, nor in invitations to positions of power in the last five years, nor in the perception of capacity to occupy the different positions of power, which was high for both sexes. Male respondents more frequently consider that activities such as participating in a scientific committee or giving a conference are not empowering. A third of both sexes consider that the SER should review its processes with a gender perspective but less than a third believe that this should be done by quotas. The reality of the last 5 years is that 1) there is a male to female ratio of 3:2 on SER boards of directors and in this period there has been no female president or treasurer; 2) in the scientific committees of the congresses men predominate (2:1) although slightly less in the local organizing committee; 3) there are more male speakers and moderators than women (very striking in satellite symposia, 4: 1); 4) 9 out of 10 editors-in-chief are men; 5) in academic positions there are 3 men for every 2 women, 9 to 1 in professorships or emeritus positions; although more women supervise residents; and 6) there are more women (60%) than men (40%) in Spanish rheumatology departments, although 75% of department chiefs are men.</p></div><div><h3>Conclusion</h3><p>Although not perceived by either the men or the women, there are biases in the involvement of women in important and leadership positions in the specialty.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45785022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}